ClinicalTrials.gg
CompletedNCT01601613Updated Jan 11, 2017

Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

A Phase 2 interventional study of activated recombinant human factor VII and placebo in Acquired Bleeding Disorder and Dengue Haemorrhagic Fever, sponsored by Novo Nordisk A/S. Completed at 9 sites in 3 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Dengue with a site in Thailand — 6 open to participants now, 8 under way, 4 of them phase 3. Dengue · Thailand.

Enrollment
18th of 23
28 · median 147
Started
2001
the only one that year
Phase 2
6 of 30
none open now
Registered
9th of 30
by date
Lead sponsor
1 of 30
Novo Nordisk A/S

Among the 30 studies in Dengue with a site in Thailand, this one is the 18th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2001, is one of 6 in phase 2, and was the 9th registered.

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

Browse Dengue studies →

Open to participants now

6 of the 30 studies in Dengue with a site in Thailand are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dengue with a site in Thailand, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).

03

Conditions studied

  • Acquired Bleeding Disorder
  • Dengue Haemorrhagic Fever

Browse trials for

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with the clinical diagnosis of Dengue Haemorrhagic Fever (DHF)
  • Patients with a clinical diagnosis of DHF Grades II and III8, requiring standard replacement therapy

Exclusion criteria

Exclusion Criteria:

  • Patients with a clinical diagnosis of DHF Grade IV
  • Known or suspected allergy to trial product or related products
  • Known to mouse, hamster or bovine protein
  • Prior treatment with activated recombinant human factor VII
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    rFVIIa

    Drug: activated recombinant human factor VII

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • 100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.

  • Drugplacebo

    100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with evidence of bleeding as assessed at 2 hours after first trial product administration

Secondary outcomes

  1. Proportion of subjects requiring standard haemostatic replacement therapy during 2 hours after first trial product administration

  2. Proportion of subjects with effective haemostatic efficacy at 2 hours after first trial product administration

  3. Coagulation related variables

  4. Adverse events

07

Study locations

9 sites
  • Novo Nordisk Investigational Site
    Kuala Lumpur, Malaysia
  • Novo Nordisk Investigational Site
    Manila, Philippines
  • Novo Nordisk Investigational Site
    Muntinlupa City, Philippines
  • Novo Nordisk Investigational Site
    Quezon City, Philippines
  • Novo Nordisk Investigational Site
    Bangkok, 10400, Thailand
  • Novo Nordisk Investigational Site
    Chiang Mai, 50200, Thailand
  • Novo Nordisk Investigational Site
    Khon Kean, 40000, Thailand
  • Novo Nordisk Investigational Site
    Pisanulok, 65000, Thailand
  • Novo Nordisk Investigational Site
    Ubonratchathani, 34000, Thailand
08

References and documents

Publications

  • Chuansumrit A, Wangruangsatid S, Lektrakul Y, Chua MN, Zeta Capeding MR, Bech OM; Dengue Study Group. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005 Nov;16(8):549-55. doi: 10.1097/01.mbc.0000186837.78432.2f. PubMed 16269927 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2001, a primary completion of Nov 2002 and a completion of Nov 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2012
First posted
May 18, 2012
Start
Jul 2001
Primary completionActual
Nov 2002
CompletionActual
Nov 2002
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01601613
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 18, 2012
Start date
Jul 2001
Primary completion
Nov 2002
Completion
Nov 2002
Last update
Jan 11, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion